 | Up a level |
Panje, Cédric; Lupatsch, J; Barbier, M; Pardo, E; Lorez, M; Dedes, K J; Aebersold, D. M.; Plasswilm, Ludwig; Gautschi, O.; Schwenkglenks, M. (2020). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Annals of oncology, 31(4), pp. 501-506. Oxford University Press 10.1016/j.annonc.2020.01.007
Kasenda, B.; Schandelmaier, S.; Sun, X.; von Elm, E.; You, J.; Blumle, A.; Tomonaga, Y.; Saccilotto, R.; Amstutz, A.; Bengough, T.; Meerpohl, J. J.; Stegert, M.; Olu, K. K.; Tikkinen, K. A. O.; Neumann, I.; Carrasco-Labra, A.; Faulhaber, M.; Mulla, S. M.; Mertz, D.; Akl, E. A.; ... (2014). Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. BMJ, 349(aug01 1), g4921-g4921. BMJ Publishing Group 10.1136/bmj.g4921
Matter-Walstra, K. W.; Dedes, K. J.; Schwenkglenks, M.; Brauchli, P.; Szucs, T. D.; Pestalozzi, B. C. (2010). Trastuzumab beyond progression: a cost-utility analysis. Annals of oncology, 21(11), pp. 2161-2168. Oxford University Press 10.1093/annonc/mdq250
